Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
Status:
Recruiting
Trial end date:
2026-03-19
Target enrollment:
Participant gender:
Summary
In patients with MRD-positive patients after AML/MDS allogeneic hematopoietic stem cell
transplantation, azacytidine combined with venetoclax may be effective in eliminating micro
residual diseases, reducing the risk of relapse, and ultimately improving long-term
survival.The primary purpose of this study was to explore an effective protocol to reduce the
risk of relapse in patients with MRD positive after allogeneic hematopoietic stem cell
transplantation for AML/MDS.
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Jinhua Central Hospital Ningbo No. 1 Hospital Second Affiliated Hospital, School of Medicine, Zhejiang University Sir Run Run Shaw Hospital Taizhou Hospital The First Affiliated Hospital of Zhejiang Chinese Medical University Union hospital of Fujian Medical University Xiangya Hospital of Central South University Yinzhou Hospital Affiliated to Medical School of Ningbo University Zhejiang Provincial People's Hospital